# Top 30 ranked extracts from small_cell_lung_NL_cleaned.json.cleaned_population.txt

=== Ranked Extract 1 (#4, Patients) — Score: 8 ===
ngfunctie onderzoek van toegevoegde
waarde zijn bij de analyse van dyspnoeklachten bij longkanker.
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Referenties
1 - Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J
Neurooncol. 1999;44(3):275-81.
2 - Hochstenbag MM, Twijnstra A, Hofman P, Wouters EF, ten Velde GP. MR-imaging of the brain of neurologic asymptomatic
patients with large cell or adenocarcinoma of the lung. Does it influence prognosis and treatment? Lung Cancer. 2003
Nov;42

=== Ranked Extract 2 (#5, Patients) — Score: 8 ===
raadpleegt u de
Referenties
1 - Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J
Neurooncol. 1999;44(3):275-81.
2 - Hochstenbag MM, Twijnstra A, Hofman P, Wouters EF, ten Velde GP. MR-imaging of the brain of neurologic asymptomatic
patients with large cell or adenocarcinoma of the lung. Does it influence prognosis and treatment? Lung Cancer. 2003
Nov;42(2):189-93.
3 - Seute T, Leffers P, ten Velde GP, Twijnstra A. Detection of brain metastases from small cell lung cancer: consequences of
changing imaging techniques (CT versus MRI). Ca

=== Ranked Extract 3 (#12, Patients) — Score: 8 ===
Row 6: Laatst geautoriseerd|: 10-05-2011 Row 1: Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de Richtlijnendatabase.
Row 2: 
Row 3: Referenties
Row 4: 
Row 5: 1 - Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neurooncol. 1999;44(3):275-81.
Row 6: 2 - Hochstenbag MM, Twijnstra A, Hofman P, Wouters EF, ten Velde GP. MR-imaging of the brain of neurologic asymptomatic patients with large cell or adenocarcinoma of the lung. Does it influence prognosis and treatment? Lung Cancer. 2003

=== Ranked Extract 4 (#13, Patients) — Score: 8 ===
enties
Row 4: 
Row 5: 1 - Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neurooncol. 1999;44(3):275-81.
Row 6: 2 - Hochstenbag MM, Twijnstra A, Hofman P, Wouters EF, ten Velde GP. MR-imaging of the brain of neurologic asymptomatic patients with large cell or adenocarcinoma of the lung. Does it influence prognosis and treatment? Lung Cancer. 2003 Nov;42(2):189-93.
Row 7: Nov;42(2):189-93.
Row 8: 3 - Seute T, Leffers P, ten Velde GP, Twijnstra A. Detection of brain metastases from small cell lung cancer: consequences of changing imagin

=== Ranked Extract 5 (#18, Patients) — Score: 8 ===
for salvage treatment in small cell lung cancer. A Southwest Oncology Group Study. Cancer 1990; 65(4):856-860.|
Row 9: 1990; 65(4):856-860.|
Row 10: 4 - Agelaki S, Syrigos K, Christophylakis C et al. A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer. Oncology 2004; 66(3):192-196.|
Row 11: 5 - Agelaki S, Veslemes M, Syrigos K et al. A multicenter phase II study of the combination of gemcitabine and docetaxel in previously treated patients with small cell lung cancer. Lung Cancer 2004; 43(3):329-333.|
Row 12: 6 - Ando

=== Ranked Extract 6 (#19, Patients) — Score: 8 ===
II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer. Oncology 2004; 66(3):192-196.|
Row 11: 5 - Agelaki S, Veslemes M, Syrigos K et al. A multicenter phase II study of the combination of gemcitabine and docetaxel in previously treated patients with small cell lung cancer. Lung Cancer 2004; 43(3):329-333.|
Row 12: 6 - Ando M, Kobayashi K, Yoshimura A et al. Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer. Lung Cancer 2004; 44(1):121-127.|
Row 13: 7 - Ardizzoni A, Manegold C, De

=== Ranked Extract 7 (#20, Patients) — Score: 8 ===
-Giron C et al. Phase II trial of biweekly irinotecan plus gemcitabine combination in refractory or relapsed small cell lung cancer (SCLC) [abstract]. Proc Am Soc Clin Oncol 2003; 21:2710.|
Row 15: 9 - Choi HJ, Cho BC, Shin SJ et al. Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy. Cancer Chemother Pharmacol 2008; 61(2):309-313.|
Row 16: 61(2):309-313|
Row 17: 10 - Christodoulou C, Kalofonos HP, Briasoulis E et al. Combination of topotecan and cisplatin in relapsed patients with s

=== Ranked Extract 8 (#21, Patients) — Score: 8 ===
nt for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy. Cancer Chemother Pharmacol 2008; 61(2):309-313.|
Row 16: 61(2):309-313|
Row 17: 10 - Christodoulou C, Kalofonos HP, Briasoulis E et al. Combination of topotecan and cisplatin in relapsed patients with small cell lung cancer: a phase II study of the hellenic cooperative oncology group (HeCOG). Cancer Chemother Pharmacol 2006; 57(2):207-212.|
Row 18: 57(2):207-212|
Row 19: 11 - Domine M, Gonzalea Larriba JL, Garcia Gomez R et al. CPT-11-gemcitabine for refractory or relapsed small cell lung c

=== Ranked Extract 9 (#24, Patients) — Score: 8 ===
Row 1: (12|) (|13) Row 1: Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de Richtlijnendatabase.
Row 2: 
Row 3: Referenties
Row 4: 
Row 5: 1 - Heymach JV, Johnson DH, Khuri FR et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. Ann Oncol 2004; 15(8):1187-1193.
Row 6: 2 - Johnson BE, Fischer T, Fischer B et al. Phase II Study of Imatinib in Patients with Small Cell Lung Cancer. Clin Cancer Res 2003; 9(16):5880-5887.
Row 7: 
Row 8: PDF aangemaakt op 23-01-2025 102/148
Row 9:  R

=== Ranked Extract 10 (#25, Patients) — Score: 8 ===
enties
Row 4: 
Row 5: 1 - Heymach JV, Johnson DH, Khuri FR et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. Ann Oncol 2004; 15(8):1187-1193.
Row 6: 2 - Johnson BE, Fischer T, Fischer B et al. Phase II Study of Imatinib in Patients with Small Cell Lung Cancer. Clin Cancer Res 2003; 9(16):5880-5887.
Row 7: 
Row 8: PDF aangemaakt op 23-01-2025 102/148
Row 9:  Row 1: Kleincellig longcarcinoom||||
Row 2: Kleincellig longcarcinoom - Targeted therapie||||
Row 3: ||||
Row 4: Uitgangsvraag||||
Row 5: ||||
Row 6: Speelt targeted thera

=== Ranked Extract 11 (#26, Patients) — Score: 8 ===
iseerd|: 10-05-2011||| Row 1: Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadple Richtlijnendatabase.|
Row 2: |
Row 3: Referenties|
Row 4: |
Row 5: 1 - Heymach JV, Johnson DH, Khuri FR et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients sensitive relapse small-cell lung cancer. Ann Oncol 2004; 15(8):1187-1193.|
Row 6: 2 - Johnson BE, Fischer T, Fischer B et al. Phase II Study of Imatinib in Patients with Small Cell Lung Cancer. Clin C 2003; 9(16):5880-5887.|Clin C
Row 7: |
Row 8: PDF aangemaakt op 23-01-2025| Row 1: 
Row 2: 
Row 3

=== Ranked Extract 12 (#27, Patients) — Score: 8 ===
erenties|
Row 4: |
Row 5: 1 - Heymach JV, Johnson DH, Khuri FR et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients sensitive relapse small-cell lung cancer. Ann Oncol 2004; 15(8):1187-1193.|
Row 6: 2 - Johnson BE, Fischer T, Fischer B et al. Phase II Study of Imatinib in Patients with Small Cell Lung Cancer. Clin C 2003; 9(16):5880-5887.|Clin C
Row 7: |
Row 8: PDF aangemaakt op 23-01-2025| Row 1: 
Row 2: 
Row 3: 
Row 4: 
Row 5: 
Row 6: om?
Row 7: 
Row 8: 
Row 9: 
Row 10: 
Row 11: 
Row 12: 
Row 13: 
Row 14: 
Row 15: 
Row 16: an het
Row 17: 
Row 18: 
Row 19: 
Row 20: r een oo

=== Ranked Extract 13 (#30, Patients) — Score: 8 ===
15: Laatst geautoriseerd|: 10-05-2011||| Row 1: Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de Richtlijnendatabase.
Row 2: 
Row 3: Referenties
Row 4: 
Row 5: 1 - Elrington GM, Murray NM, Spiro SG et al. Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients. J Neurol Neurosurg Psychiatry 1991;54:764–767
Row 6: 2 - Hawley RJ, Cohen MH, Saini N, Armbrustmacher VW. The carcinomatous neuromyopathy of oat cell lung cancer. Ann Neurol 1980;7:65–72
Row 7: 3 - ONeill, Murray NM, Newsom-Davis J,

=== Ranked Extract 14 (#31, Patients) — Score: 8 ===
verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de Richtlijnendatabase.
Row 2: 
Row 3: Referenties
Row 4: 
Row 5: 1 - Elrington GM, Murray NM, Spiro SG et al. Neurological paraneoplastic syndromes in patients with small cell lung cancer. A prospective survey of 150 patients. J Neurol Neurosurg Psychiatry 1991;54:764–767
Row 6: 2 - Hawley RJ, Cohen MH, Saini N, Armbrustmacher VW. The carcinomatous neuromyopathy of oat cell lung cancer. Ann Neurol 1980;7:65–72
Row 7: 3 - ONeill, Murray NM, Newsom-Davis J, The Lambert-Eaton myasthenic sydrome. A review of 50 cases. Brain

=== Ranked Extract 15 (#3, Patients) — Score: 7 ===
amar A, Pujol JL. Pro-gastrin-releasing peptide, neuron specific enolase and chrom
serum markers of small cell lung cancer. Lung Cancer 2000 September;29(3):197-203.
2 - Ebert W, Muley T, Trainer C, Dienemann H, Drings P. Comparison of changes in the NSE levels with clinic
the therapy monitoring of patients with SCLC. Anticancer Res 2002 March;22(2B):1083-9.
3 - Molina R. ProGRP: A New Biomarker for Small Cell Lung Cancer. Eur J Clin Med Oncol 2010 February;2
4 - Stieber P, Dienemann H, Schalhorn A, Schmitt UM, Reinmiedl J, Hofmann K, Yamaguchi K. Pro-gastrin-re
(ProGRP)--a useful marker in small cell

=== Ranked Extract 16 (#7, Patients) — Score: 7 ===
antoni U, Festi G, Sartori F: Long term results of surgery and
chemotherapy in small cell lung cancer. Eur J Cardiothorac Surg 1998; 14(4):398-402.
13 - Tsuchiya R, Suzuki K, Ichinose Y, Watanabe Y, Yasumitsu T, Ishizuka N, Kato H: Phase II trial of postoperative adjuvant
cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology
Lung Cancer Study Group Trial (JCOG9101). J Thorac Cardiovasc Surg 2005; 129(5):977-983.
14 - Wada H, Yokomise H, Tanaka F, Hirata T, Fukuse T, Bando T, Inui K, Ike O, Mizuno H, Hitomi S: Surgical treatment of

=== Ranked Extract 17 (#8, Patients) — Score: 7 ===
o T, Inui K, Ike O, Mizuno H, Hitomi S: Surgical treatment of
small cell carcinoma of the lung: advantage of preoperative chemotherapy. Lung Cancer 1995; 13(1):45-56.
15 - Hanagiri T, Sugio K, Baba T, Ichiki Y, Yasuda M, Uramoto H, Ohga T, Takenoyama M, Yasumoto K: Results of surgical
treatment for patients with small cell lung cancer. J Thorac Oncol 2009; 4(8):964-968
Kleincellig longcarcinoom - Inductiechemotherapie gevolgd door chirurgie
Uitgangsvraag
Waaruit bestaat de behandeling van patiënten met limited disease kleincellig loncarcinoom?
Aanbeveling
Voor patiënten met stadium I-II SCLC is chirur

=== Ranked Extract 18 (#9, Patients) — Score: 7 ===
o F, Bruno J, Chella A, Angeletti CA: Surgery plus adjuvant chemothera
small-cell lung cancer. Rationale for current approach. Am J Clin Oncol 1991; 14(3):218-224.
13 - Tsuchiya R, Suzuki K, Ichinose Y, Watanabe Y, Yasumitsu T, Ishizuka N, Kato H: Phase II trial of postop
cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan C
Lung Cancer Study Group Trial (JCOG9101). J Thorac Cardiovasc Surg 2005; 129(5):977-983.
14 - Wada H, Yokomise H, Tanaka F, Hirata T, Fukuse T, Bando T, Inui K, Ike O, Mizuno H, Hitomi S: Surgic
small cell carcinoma of the lu

=== Ranked Extract 19 (#10, Patients) — Score: 7 ===
anaka F, Hirata T, Fukuse T, Bando T, Inui K, Ike O, Mizuno H, Hitomi S: Surgic
small cell carcinoma of the lung: advantage of preoperative chemotherapy. Lung Cancer 1995; 13(1):45-56
15 - Hanagiri T, Sugio K, Baba T, Ichiki Y, Yasuda M, Uramoto H, Ohga T, Takenoyama M, Yasumoto K: Re
treatment for patients with small cell lung cancer. J Thorac Oncol 2009; 4(8):964-968
For the ISC-
ment of smal
apy for T1-3N
perative adjuv
Clinical Onco
cal treatmen
esults of surg
-Lung
ll cell
N0M0
vant
ology
nt of
gical
Kleincellig longcarcinoom - Systemische behandeling en radiother
Uitgangsvraag
Waaruit bestaat de

=== Ranked Extract 20 (#15, Patients) — Score: 7 ===
w 1: 19(8):2114-2122.
Row 2: 1 Row 1: PDF aangemaakt op 23-01-2025 39/148
Row 2: 
Row 3:  Row 1: 
Row 2: 
Row 3: Kleincellig longcarcinoom
Row 4: 
Row 5: T, Fukuoka M: Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902. J Clin Oncol 2006; 24(33):5247-5252.
Row 6: Clin Oncol 2006; 24(33):5247-5252
Row 7: 2 Row 1: Inst 2005; 97(9):666-674.
Row 2: 2 Row 1: 
Row 2: PDF aangemaakt op 23-01-2025 40/148 Row 1: Kleincellig longcarcinoom|

=== Ranked Extract 21 (#16, Patients) — Score: 7 ===
evidence tabellen en eventuele aanverwante producten raadpleegt u de Richtlijnendatabase.
Row 2: 
Row 3: Referenties
Row 4: 
Row 5: 1 - Shepherd FA, Giaccone G, et al. (2002). "Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer." J Clin Oncol 20(22): 4434-9.
Row 6: 4434-9.
Row 7: 2 - Pujol JL, Breton JL, et al. (2007). "Phase III double-blind, placebo-cont

=== Ranked Extract 22 (#17, Patients) — Score: 7 ===
1987;||
Row 7: 3 - Vincent M, Evans B, Smith I. First-line chemotherapy rechallenge after relapse in small cell lung cancer. Cancer Chemother Pharmacol 1988; 21(1):45-48.|||Cancer Chemother
Row 8: 4 - Collard P, Weynants P, Francis C et al. Treatment of relapse of small cell lung cancer in selected patients with the initial combination chemotherapy carboplatin, etoposide, and epirubicin. Thorax 1992; 47(5):369-371.|||
Row 9: 5 - Batist G, Ihde DC, Zabell A et al. Small-cell carcinoma of lung: reinduction therapy after late relapse. Ann Intern Med 1983 98(4):472-474.||Ann Intern Med 1983|
Row 10: |||
R

=== Ranked Extract 23 (#22, Patients) — Score: 7 ===
rales S et al. Gemcitabine and paclitaxel as second line treatment in small cell lung cancer (SCLC) A multicentric phase II study. [abstract]. Proc Am Soc Clin Oncol 2001; 20.|
Row 21: 13 - Dongiovanni V, Buffoni L, Berruti A et al. Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial. Cancer Chemother Pharmacol 2006; 58(2):203-209.|
Row 22: Pharmacol 2006; 58(2):203-209.|
Row 23: 14 - Dudek AZ, Lesniewski-Kmak K, Bliss RL et al. Pilot phase II study of gemcitabine and vinorel

=== Ranked Extract 24 (#23, Patients) — Score: 7 ===
all-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial. Cancer Chemother Pharmacol 2006; 58(2):203-209.|
Row 22: Pharmacol 2006; 58(2):203-209.|
Row 23: 14 - Dudek AZ, Lesniewski-Kmak K, Bliss RL et al. Pilot phase II study of gemcitabine and vinorelbine in patients with recurrent or refractory small cell lung cancer. Lung 2005; 183(1):43-52.|
Row 24: 15 - Evans WK, Osoba D, Feld R et al. Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer. J Clin Oncol 1985; 3(1):65-71.|
Row 25: PDF aangemaakt op 23-01-2025 99/148|
Ro

=== Ranked Extract 25 (#28, Patients) — Score: 7 ===
7;315:1219-1222|.|
Row 2: 4||||Curr Clin Nutr Metab Care 1999;2:339- Row 1: 5|- Body JJ. The syndrome of anorexia-cachexia.|Clin Opin Oncol 1999;11:255-260|
Row 2: 6||| Row 1: Clin oncol 1993;11:2043-9.
Row 2: 7 Row 1: 1|0 - Willox JC, Corr J, Shaw J, et al. Prednisolone as an appetite stimulant in patients with cancer.||Br Med J 1984;288:27.||
Row 2: 1|1 - Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer.|Drugs 1998;55:675–688.|||
Row 3: 1||||| Row 1: 1|3 - Mantovani G, Maccio A, Massa E, et al. Managing cancer-related anorexia / cachexia.||||Drugs 2001;61:499–514

=== Ranked Extract 26 (#29, Patients) — Score: 7 ===
ucten raadpleegt u Richtlijnendatabase.
Row 4: 
Row 5: Referenties
Row 6: 
Row 7: 1 Row 1: 3|- Bruera E. Anorexia, cachexia and nutrition.|B Med J 1997;315:1219-1222|.|
Row 2: 4||||Curr Clin Nutr Metab Care 1999 Row 1: 1|0 - Willox JC, Corr J, Shaw J, et al. Prednisolone as an appetite stimulant in patients with cancer.||Br Med J 1984;288:2|
Row 2: 1|1 - Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer.|Drugs 1998;55:675–688.||
Row 3: 1|||| Row 1: 1|3 - Mantovani G, Maccio A, Massa E, et al. Managing cancer-related anorexia / cachexia.||||Drugs 2001;61:499–514.|||

=== Ranked Extract 27 (#1, Population) — Score: 2 ===
Etoposide: a new anti-cancer agent.|Lancet 1981: II (8252) 912-5|
Row 2: 1||| Row 1: 1|7 - Taal BG, Beijnen JH, Teller FG, et al. Bioavailability of oral etoposide in gastric cancer.|Eur J cancer 1994: 30A (3): 420-1||
Row 2: 1|||Ann Oncol 1993; 4| Row 1: 1|9 - Toffoli G, Corona G, Sorio R, et al. Population pharmacokinetics and pharmacodynamics of oral etoposide.|Br J Clin|
Row 2: |||
Row 3: PDF aangemaakt op 23-01-2025 65/148|||
Row 4: ||| Row 1: |
Row 2: |
Row 3: Kleincellig longcarcinoom|
Row 4: |
Row 5: pharmacol 2001; 52 (50: 511-9|
Row 6: 2| Row 1: 2
Row 2: Eur J Cancer 1993; 29A (10): 1479-81
R

=== Ranked Extract 28 (#2, Population) — Score: 2 ===
asthenia Gravis by 3,4- Diaminopyridine. European Archives of Psychiatry and Clinical Neuroscience. 1984: 234; 6: 374-377, DOI: 10.1007/BF00386054
Row 9: 10.1007/BF00386054
Row 10: 5 - Hill CL, Zhang Y, Sigurgeirsson B et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001;357:96–100.
Row 11: 
Row 12: PDF aangemaakt op 23-01-2025 131/148 Row 1: Kleincellig longcarcinoom|||||
Row 2: Kleincellig longcarcinoom - Overige paraneoplastische syndromen|||||
Row 3: |||||
Row 4: Renale manifestaties van non-renale kanker|||||
Row 5: Glomerulaire afwijk

=== Ranked Extract 29 (#6, Patients) — Score: 2 ===
Rosenman
JG, eds. Diagnosis and treatment of lung cancer: an evidence-based guide for the practicing clinician, 25, 2001. Pp 360-75.
Philadelphia: W.B. Saunders Company.
2 - Cerry T, Anderson H, Bramwell V, Thatcher N. Pretreatment prognostic factors and scoring system in 407 small-cell lung
cancer patients. International Journal of Cancer 1987; 39 (2): 146-9 Uitgangsvraag
Welk stadiëringssysteem moet worden gebruikt bij het indelen van patiënten met kleincellig longcarcinoom?
Aanbeveling
Patiënten met een SCLC moeten gestadieerd worden volgens de nieuwe TNM classificatie (7de editie).
Onderbouwing
Co

=== Ranked Extract 30 (#11, Patients) — Score: 2 ===
Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C; SALT Investigators. Tolvaptan, a
selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006 Nov 16;355(20):2099-112. Epub 2006
Nov 14
4 - Munger MA. New agents for managing hyponatremia in hospitalized patients. Am J Health Syst Pharm. 2007 Feb
5 - Radulescu D, Pripon S, Bunea D, Ciuleanu TE, Radulescu LI. Endocrine paraneoplastic syndromes in small cell lung
carcinoma. Two case reports. J BUON. 2007 Jul-Sep;12(3):411-4
6 - Botea V, Edelson GW, Munasinghe RL . Hyperparathyroidism, hypercalcemia, and calci

